B01 VENETOCLAX TARGETED THERAPY in AL AMYLOIDOSIS PATIENTS: A RETROSPECTIVE ANALYSIS FROM THE FRENCH AMYLOIDOSIS NETWORK
Murielle Roussel(Centre Hospitalier Universitaire de Limoges), Arnaud Jaccard(Centre Hospitalier Universitaire de Limoges), Michelle Pirotte(University of Liège), Benjamin Carpentier, Éstelle Desport(Centre Hospitalier Universitaire de Poitiers), Margaret Macro(Hôpital Cochin), M.R. Vignon(Institut National de la Recherche Agronomique), Thomas Chalopin(Centre Hospitalier Universitaire de Tours), Bruno Royer(Centre Hospitalier Universitaire Amiens-Picardie), Romain Gounot(Assistance Publique – Hôpitaux de Paris), K. Queru(Hôpital Dupuytren), Frank Bridoux(Université de Poitiers), Émilie Chalayer(Institute Cancer De La Loire Lucien Neuwirth), O. Decaux(Centre Hospitalier Universitaire de Rennes), M. Niault(Centre Hospitalier de Bretagne Sud), A.-M. Stoppa(Institut Paoli-Calmettes), Oscar Rizzo(Institut Jules Bordet), Stéphanie Harel(Hôpital Saint-Louis), A. Huart(Hôpital Rangueil), Lionel Karlin(Hôpital Lyon Sud)
Cited by 5
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
|Journal of Clinical Oncology|2012|965
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
|Kidney International|2021|809